SPL-028 is under clinical development by Cybin and currently in Phase I for Generalized Anxiety Disorder (GAD). According to GlobalData, Phase I drugs for Generalized Anxiety Disorder (GAD) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SPL-028’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SPL-028 overview
SPL-028 is under development for the treatment of major depressive disorder (MDD) and generalized anxiety disorder . The drug candidate is a deuterium-enriched tryptamine. It is administered through intravenous and intramuscular route.
Cybin overview
Cybin is a clinical-stage biopharmaceutical company that develops psychedelic drugs to treat mental health conditions. The company’s pipeline products include CYB003, CYB004 and CYB005. Its CYB003 is a deuterated psiloCybin analog that treats major depressive disorder and alcohol use disorder; CYB004 is a deuterated dimethyltryptamine that treats generalized anxiety disorder. Cybin’s CYB005 is a phenethylamine derivative that treats neuroinflammation. The company works in partnership with Clinilabs Drug Development Corporation, the University of Washington and Greenbrook TMS. The company operates in Canada and the US. Cybin is headquartered in Toronto, Ontario, Canada.
For a complete picture of SPL-028’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.